Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tereza Cairns

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Kidney Journal|February 13, 2019
Will the FAbry STabilization indEX make its way to everyday clinical practice?Tereza Cairns, Christoph Wanner
Molecular Genetics and Metabolism Reports|November 4, 2024
Impact of the Covid19 pandemic on health-related quality of life in patients with Fabry disease - implications for future care of patients with rare diseasesVictoria Sokalski, Kolja Lau, Tereza Cairns, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
Molecular Genetics & Genomic Medicine|February 25, 2022
Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)Kolja Lau, Nurcan Üçeyler, Tereza Cairns, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearJonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Kidney Journal|February 13, 2019
Will the FAbry STabilization indEX make its way to everyday clinical practice?Tereza Cairns, Christoph Wanner
Molecular Genetics and Metabolism Reports|November 4, 2024
Impact of the Covid19 pandemic on health-related quality of life in patients with Fabry disease - implications for future care of patients with rare diseasesVictoria Sokalski, Kolja Lau, Tereza Cairns, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
Molecular Genetics & Genomic Medicine|February 25, 2022
Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)Kolja Lau, Nurcan Üçeyler, Tereza Cairns, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearJonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Pageof 1